AR and acne: Promising therapies include the modulation of AR signaling, which can be modified in different ways, such as with ASC-J9, an enhancer of AR degradation that suppressed bladder cancer in pre-clinical trials (only clinical trials for acne are currently registered) and AZD 5312, an AR antisense oligonucleotide that has already completed phase I clinical trials for solid tumors [120,121,122,123].